# REPL earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/REPL) · [Earnings tab](https://www.lopjlb.com/stock/REPL?tab=earnings)

Updated: 2026-08-10T10:19:39

Quarters analyzed: 1

## Cross-quarter narrative

Replimune's latest call centers on the impending PDUFA date (July 22, 2025) for RP1 in anti-PD-1 failed melanoma. The company has built commercial infrastructure ahead of a potential approval and holds $483.8M in cash, providing runway into Q4 2026. The confirmatory Ignite 3 trial is actively enrolling, and ASCO data readouts are anticipated. Management tone scored 0.8, reflecting confidence in regulatory progress and preparation. No specific demand, margin, or capital concerns were highlighted, and no milestones, delays, or fears were explicitly flagged in this summary.

## Latest CallCard · Q4

Replimune prepares for potential RP1 approval (PDUFA July 22, 2025) in anti-PD-1 failed melanoma with commercial infrastructure built, $483.8M cash runway into Q4 2026, Ignite 3 confirmatory trial enrolling, and ASCO data upcoming.','tone': {'mgmt': 0.8, 'mgmt_rationale': 'Management highlights regu

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2025 Q4:** Replimune prepares for potential RP1 approval (PDUFA July 22, 2025) in anti-PD-1 failed melanoma with commercial infrastructure built, $483.8M cash runway into Q4 2026, Ignite 3 confirmatory trial enrolling, and ASCO data upcoming.','tone': {'mgmt': 0.8, 'mgmt_rationale': 'Management highlights regu

## Theme arcs

- **Regulatory progress toward RP1 approval** (new): PDUFA date set for July 22, 2025; commercial infrastructure in place
- **Clinical development pipeline** (new): Ignite 3 confirmatory trial enrolling; ASCO data upcoming
- **Financial runway** (new): $483.8M cash provides runway into Q4 2026
- **Commercial readiness** (new): Infrastructure built ahead of potential approval

## Guidance path

2025 Q4:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/REPL`